Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anti-Meth Draft Places PSE Behind Counter, Lacks Schedule V Language

This article was originally published in The Tan Sheet

Executive Summary

Current draft report language in the Patriot Act places all pseudoephedrine products behind the counter but does not contain a Schedule V provision, according to the Consumer Healthcare Products Association

You may also be interested in...



CHPA Year In Review: Legislative Accomplishments, OTC Product Awareness And Goals For 2006

The Consumer Healthcare Products Association speaks to "The Tan Sheet" about the group's accomplishments in 2005 and plans for 2006. The 125 year-old trade association represents the interests of the consumer healthcare and over-the-counter drugs industries. Find below excerpts from an interview with CHPA President Linda Suydam and Vice President - Government Relations Kevin Kraushaar

Patriot Act and PSE

Provisions requiring behind-the-counter placement of products containing pseudoephedrine have been added to the final version of the conference report for the Patriot Act reauthorization package. The report was filed Dec. 8 and will be considered by the House and Senate during the week of Dec. 12, House Judiciary Committee Chairman James Sensenbrenner (R-Wis.), announces. The provision for BTC sale was first added to the draft version of the conference report in November (1"The Tan Sheet" Nov. 28, 2005, p. 3). Also added at that time were essentially all elements of the Talent/Feinstein Combat Meth Act (S 103), except for the provision requiring Schedule V status for pseudoephedrine. The conference report's final version contains a new pseudoephedrine sales limit of 9 g/30 days...

Patriot Act and PSE

Provisions requiring behind-the-counter placement of products containing pseudoephedrine have been added to the final version of the conference report for the Patriot Act reauthorization package. The report was filed Dec. 8 and will be considered by the House and Senate during the week of Dec. 12, House Judiciary Committee Chairman James Sensenbrenner (R-Wis.), announces. The provision for BTC sale was first added to the draft version of the conference report in November (1"The Tan Sheet" Nov. 28, 2005, p. 3). Also added at that time were essentially all elements of the Talent/Feinstein Combat Meth Act (S 103), except for the provision requiring Schedule V status for pseudoephedrine. The conference report's final version contains a new pseudoephedrine sales limit of 9 g/30 days...

Related Content

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel